I still can't believe this post of his is real, but it is.
I had to look it up to make sure it wasn't fake.
From actual post history: Mar 15, 2013 $8.46 - shortfishfry 3:16 PM, ".... buy, buy, buy!!!!"
I still can't believe he shows his face on yahoo after seeing his posting history.
After losing all his money, he is back again. Like a bad rash or a curse.
I've seen some suggest he is like the Pied Piper leading the poor children to slaughter.
No one ever saw those children again.
doubt most of the time they are even traders, more likely tweebs, having lost their allowance by Tuesday, nothing better to do till mom hands over more coin.
Raf I think you are reading way to much in to what is written on a stock message board and the correlation of how the stock or company will perform. Most of these new posters are just traders working both sides of the trade. The traders will settle down once a decision comes down regarding Nce. The stock will also settle down as the next catalyst of reduce it is a ways off. Full disclosure I have joined the traders and have already made one successful trade in the low $2's to just under $3. I just got back in on Friday at $2.29 and will play the Nce decision and then right back out again.
Yes, desperation is correct. They are threatened by Vascepa and doing a terrible job trying to deceive anyone reading their #$%$. Good thing most everyone on here knows better.
This week the Basher's fear is script growth. They are doing mathematical gymnastics trying to make 2+2 =1. And they're trying to frustrate keystone hoping he quits posting scripts all together.
They know that it will be impossible to convince investors to sell when they see Vascepa steadily capturing market share with such a small sales force and virtually no marketing. This drug, in the hands of BP, will be a mega Block Buster.
The most entertaining addition as of late is Mario the soft basher. He's a "long" who, out of the goodness of his heart, insists that we 'kids' all SELL some of our core position to free up shares to short SELL. These guys aren't smart enough to be manipulative. Sit back and let them entertain us is the way I look at it. I'm sure having a Message board management career is miserable enough but I'm happy to make it just a bit more miserable. :)
Finally, some key comments have come out straight from the horse's mouth -- Glaxosmithkline (NYSE:GSK) -- strengthening Amarin's (NASDAQ:AMRN) Vascepa's NCE prospects like never before. GlaxoSmithKline and Pronova (now a part of BASF (OTCQX:BASFY)), the two key players in the prescription grade Omega-3 fatty acid space, responded to the February 6, 2013 citizen petition filed by Crowell & Moring LLP.
The petition provided some recommendations for FDA to implement, one of which included listing EPA ethyl ester and DHA ethyl ester as active ingredients of Lovaza. Vascepa's NCE dreams would shatter if FDA is about to follow this recommendation, but that seems very unlikely as GSK/Pronova have opposed each and every request and recommendations made in the petition.- seeking alpha
Sentiment: Strong Buy
4/19 Patent infringers usually claim that their product does not infringe at all. With Amarin having 40 plus patents on Vascepa, all they will need to prove is that the generics are infringing on at least one of their patents. They also claim that the patents should never have been granted by the patent office. Amarin's patents seem to have been carefully vetted by several levels of the patent office over a significant period of time before being granted. This should auger well for Amarin when they are challenged. However, like most court disputes, these cases can be long and drawn out and expensive. - ziploc
Sentiment: Strong Buy
It's so great to see these complete morons (or just one moron) work on weekends by posting nonsense. The more posts, the better it is for longs, because these posts clearly show desperation. Curious which catalyst they fear mostly, is it the NCE decision, ex-USA partnershipSSS, REDUCE-IT interim or a BUYOUT?
Prescription figures still very disturbing.
Look at Vascepa's TR x trend.
2013 brought us to 5,500 total weekly prescriptions.
2014 brought us another 5,500 total weekly prescriptions.
2015 has brought us 260 total weekly prescriptions so far.
We currently sit at 11,260 total weekly prescriptions.
The growth trend? Was FLAT now DOWN - sharp downward turn.
People can obtain Vascepa off label but nobody is. Nobody is choosing Vascepa for extremely high triglycerides either. With TR x falling off a cliff, we will soon see how income has been affected. We need the quarterly reports to see just how bad this drop off hurts financially.
Why is a generic Omega-3 acid ethyl ester that is FDA approved for the identical indication as Vascepa destroying Vascepa and Lovaza and Epanova.
Why does "keystone.investments" not post Epanova prescription figures? Are they a lot better than Vascepa?
There are some unsophisticated persons jumping around pretending to be happy when they see the feeble prescription figures for Vascepa (see below).
Every week the numbers look worse and every week the same flat-heads jump in and post rubbish like, "Excellent scripts!"
The trend is horrid and everybody knows it. You can shine this up to look like anything other than what it is....a real smelly floater.
$6.17 "I have my "All in" orders in place."
You are clearly the board flunky. Always claiming to be "all in" while posting like the corn cob you are.
You post on the board that you are all in - and now you claim you never were. Then you post that you haven't sold a share - and now you claim you sold all your shares, quietly and then waited years before revealing this fact. Congratulations on being exposed again and butt hurt once more ya filthy wiper.
AMRN Price per share $6.17 - shortfishfry says, "I have my "All in" orders in place."
This guy is a genuine wiper.
Look at prescription figures posted on this board (by keystone.investments).
2013 brought us to 5,500 total new weekly prescriptions. (not good)
2014 brought us another 5,500 total new weekly prescriptions. (still not good) ( now trend is flat)
2015 has brought us 260 total new weekly prescriptions so far. (alarmingly low) (now trend is collapsing)
Total new Vascepa prescriptions after 2 years and 3.5 months - 11,260 new weekly prescriptions. This is hideous.